Comparison of different immunoprophylaxis regimens after liver transplantation with hepatitis B core antibody–positive donors: A systematic review

Sammy Saab, Benjamin Waterman, Amanda C. Chi, Myron J. Tong – 12 January 2010 – Orthotopic liver transplantation (OLT) recipients without hepatitis B virus (HBV) infection who receive liver grafts from antibody to hepatitis B core antigen–positive [HBcAb(+)], hepatitis B surface antigen–negative [HBsAg(−)] donors have an increased risk of developing de novo hepatitis B infection.

Tumor recurrence following liver transplantation for hepatocellular carcinoma: Role of tumor proliferation status

Aileen E. Marshall, Simon M. Rushbrook, Sarah L. Vowler, Christopher R. Palmer, R. Justin Davies, Paul Gibbs, Susan E. Davies, Nicholas Coleman, Graeme J. M. Alexander – 12 January 2010 – The selection of patients with hepatocellular carcinoma for liver transplantation is currently based on the size and number of tumors to minimize the risk of recurrence. These criteria measure tumor bulk but may not reflect tumor behavior accurately. A biological marker of tumor behavior could aid with patient selection further.

Epigenetic silence of ankyrin‐repeat–containing, SH3‐domain–containing, and proline‐rich‐region– containing protein 1 (ASPP1) and ASPP2 genes promotes tumor growth in hepatitis B virus–positive hepatocellular carcinoma

Jian Zhao, Guobin Wu, Fangfang Bu, Bin Lu, Anmin Liang, Lei Cao, Xin Tong, Xin Lu, Mengchao Wu, Yajun Guo – 23 December 2009 – The ankyrin‐repeat–containing, SH3‐domain–containing, and proline‐rich‐region–containing protein (ASPP) family of proteins regulates apoptosis through interaction with p53 and its family members. This study evaluated the epigenetic regulation of ASPP1 and ASPP2 in hepatitis B virus (HBV)‐positive hepatocellular carcinoma (HCC) and explores the effects of down‐regulation of ASPP1 and ASPP2 on the development of HCC.

Use of sorafenib in patients with hepatocellular carcinoma before liver transplantation: A cost‐benefit analysis while awaiting data on sorafenib safety

Alessandro Vitale, Michael L. Volk, Davide Pastorelli, Sara Lonardi, Fabio Farinati, Patrizia Burra, Paolo Angeli, Umberto Cillo – 23 December 2009 – The role of bridging therapies for patients with hepatocellular carcinoma (HCC) on the waiting list for liver transplantation (LT) remains controversial. There is strong evidence to support the effectiveness of sorafenib in extending the time to progression of HCC.

Role of acid sphingomyelinase of Kupffer cells in cholestatic liver injury in mice

Yosuke Osawa, Ekihiro Seki, Masayuki Adachi, Atsushi Suetsugu, Hiroyasu Ito, Hisataka Moriwaki, Mitsuru Seishima, Masahito Nagaki – 23 December 2009 – Kupffer cells, resident tissue macrophages of the liver, play a key role in the regulation of hepatic inflammation, hepatocyte death, and fibrosis that characterize liver diseases. However, it is controversial whether Kupffer cells promote or protect from liver injury.

Generation of functional human hepatic endoderm from human induced pluripotent stem cells

Gareth J. Sullivan, David C. Hay, In‐Hyun Park, Judy Fletcher, Zara Hannoun, Catherine M. Payne, Donna Dalgetty, James R. Black, James A. Ross, Kay Samuel, Gang Wang, George Q. Daley, Je‐Hyuk Lee, George M. Church, Stuart J. Forbes, John P. Iredale, Ian Wilmut – 23 December 2009 – With the advent of induced pluripotent stem cell (iPSC) technology, it is now feasible to generate iPSCs with a defined genotype or disease state.

Subscribe to